Keyphrases
Related Disorders
100%
Meta-analysis
100%
Obsessive-compulsive Disorder
100%
Glutamatergic
100%
Systematic Meta-analysis
100%
Randomized Clinical Trial
25%
Certainty of Evidence
16%
Cohen's d
16%
Refractoriness
16%
Yale-Brown Obsessive-Compulsive Scale (Y-BOCS)
16%
Novel Therapeutics
8%
Placebo
8%
Placebo-controlled
8%
Data Synthesis
8%
Dose Effect
8%
Subgroup Analysis
8%
Selective Serotonin Reuptake Inhibitors
8%
Psychotherapy
8%
Sensitivity Analysis
8%
Augmentation Strategy
8%
Monotherapy
8%
Daily Functioning
8%
Disorder-specific
8%
PubMed
8%
Neuropsychiatric Conditions
8%
Large Sample Size
8%
Data Extraction
8%
High Heterogeneity
8%
Obsessive-compulsive Disorder Symptoms
8%
Mean Reduction
8%
Random-effects Meta-analysis
8%
Publication Bias
8%
Web of Science
8%
Embase
8%
Leave-one-out
8%
Risk of Bias
8%
PsycINFO
8%
Electronic Search
8%
Double-blind Randomized Clinical Trial
8%
Cochrane Central Register of Controlled Trials
8%
Sex-gender
8%
Non-English
8%
Strategy Risk
8%
English Studies
8%
Synthesis Data
8%
Standardized Mean Difference
8%
Nursing and Health Professions
Meta Analysis
100%
Systematic Review
100%
Obsessive Compulsive Disorder
100%
Placebo
66%
Yale Brown Obsessive Compulsive Scale
66%
Effect Size
33%
Sample Size
33%
Monotherapy
33%
Medline
33%
Cochrane Library
33%
PsycINFO
33%
Embase
33%
Data Extraction
33%
Data Synthesis
33%
Selective Serotonin Reuptake Inhibitor
33%
Medicine and Dentistry
Meta-Analysis
100%
Systematic Review
100%
Disease
100%
Randomized Clinical Trial
40%
Placebo
20%
Obsessive Compulsive Disorder
20%
Yale-Brown Obsessive Compulsive Scale
20%
Effect Size
10%
Monotherapy
10%
Selective Serotonin Reuptake Inhibitor
10%
Subgroup Analysis
10%
Obsessive-Compulsive Disorder Symptoms
10%
Neuroscience
Placebo
100%
Obsessive-Compulsive Disorder
100%
Meta-Analysis
100%
Selective Serotonin Reuptake Inhibitor
50%
Obsessive-Compulsive Disorder Symptoms
50%
Pharmacology, Toxicology and Pharmaceutical Science
Randomized Clinical Trial
100%
Obsessive Compulsive Disorder
75%
Placebo
50%
Selective Serotonin Reuptake Inhibitor
25%
Monotherapy
25%